Pimavanserin increases mortality in elderly with Parkinson's disease: Study
According to a new study published in the Journal Neurology, older persons with Parkinson's disease (PD) who used pimavanserin had an increased risk of hospitalization and death at particular time points after initiation compared to nonusers.
This study validates the prior concerns regarding use of pimavanserin and the risks it brings when chosen to use it in case of Parkinson's disease (PD). It also stated the association of typical and atypical antipsychotic drugs with increased death rate in Parkinson's disease (PD) patients.
From November 1, 2015 to December 31, 2018, Hwang and colleagues conducted a retrospective cohort analysis to examine the risk of hospitalization and mortality associated with pimavanserin usage among individuals 65 years and older with Parkinson's disease (PD) .The data was obtained via an administrative dataset on residents of Medicare-certified long-term care facilities and linked Medicare claims data.
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.